US20160287764A2 - Bursitis treatment device and method - Google Patents
Bursitis treatment device and method Download PDFInfo
- Publication number
- US20160287764A2 US20160287764A2 US14/728,897 US201514728897A US2016287764A2 US 20160287764 A2 US20160287764 A2 US 20160287764A2 US 201514728897 A US201514728897 A US 201514728897A US 2016287764 A2 US2016287764 A2 US 2016287764A2
- Authority
- US
- United States
- Prior art keywords
- bursa
- rinsing aid
- temperature
- treatment method
- bursitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010006811 Bursitis Diseases 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title claims description 42
- 241001260012 Bursa Species 0.000 claims abstract description 162
- 206010061218 Inflammation Diseases 0.000 claims abstract description 25
- 230000004054 inflammatory process Effects 0.000 claims abstract description 25
- 230000008030 elimination Effects 0.000 claims abstract description 9
- 238000003379 elimination reaction Methods 0.000 claims abstract description 9
- 239000012528 membrane Substances 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 239000000470 constituent Substances 0.000 claims description 9
- 239000003292 glue Substances 0.000 claims description 5
- 206010015866 Extravasation Diseases 0.000 claims description 4
- 239000002872 contrast media Substances 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 230000036251 extravasation Effects 0.000 claims description 4
- 238000004026 adhesive bonding Methods 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 239000002699 waste material Substances 0.000 claims description 3
- 230000000149 penetrating effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 abstract description 41
- 238000007710 freezing Methods 0.000 abstract description 6
- 230000008014 freezing Effects 0.000 abstract description 6
- 238000003780 insertion Methods 0.000 description 15
- 230000037431 insertion Effects 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 14
- 238000002203 pretreatment Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 206010011732 Cyst Diseases 0.000 description 10
- 208000031513 cyst Diseases 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 239000003518 caustics Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000007460 surgical drainage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000009989 Posterior Leukoencephalopathy Syndrome Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241001466077 Salina Species 0.000 description 1
- 101100194362 Schizosaccharomyces pombe (strain 972 / ATCC 24843) res1 gene Proteins 0.000 description 1
- 101100194363 Schizosaccharomyces pombe (strain 972 / ATCC 24843) res2 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000000459 calcaneus Anatomy 0.000 description 1
- 238000005524 ceramic coating Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000006223 plastic coating Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D03—WEAVING
- D03C—SHEDDING MECHANISMS; PATTERN CARDS OR CHAINS; PUNCHING OF CARDS; DESIGNING PATTERNS
- D03C3/00—Jacquards
- D03C3/20—Electrically-operated jacquards
-
- A61M1/0058—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/77—Suction-irrigation systems
- A61M1/772—Suction-irrigation systems operating alternately
-
- D—TEXTILES; PAPER
- D03—WEAVING
- D03C—SHEDDING MECHANISMS; PATTERN CARDS OR CHAINS; PUNCHING OF CARDS; DESIGNING PATTERNS
- D03C1/00—Dobbies
- D03C1/005—Electronic dobbies
-
- D—TEXTILES; PAPER
- D03—WEAVING
- D03C—SHEDDING MECHANISMS; PATTERN CARDS OR CHAINS; PUNCHING OF CARDS; DESIGNING PATTERNS
- D03C13/00—Shedding mechanisms not otherwise provided for
-
- D—TEXTILES; PAPER
- D03—WEAVING
- D03C—SHEDDING MECHANISMS; PATTERN CARDS OR CHAINS; PUNCHING OF CARDS; DESIGNING PATTERNS
- D03C3/00—Jacquards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
- A61M2205/3372—Temperature compensation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/366—General characteristics of the apparatus related to heating or cooling by liquid heat exchangers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0279—Cannula; Nozzles; Tips; their connection means
- A61M3/0283—Cannula; Nozzles; Tips; their connection means with at least two inner passageways, a first one for irrigating and a second for evacuating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/44—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for cooling or heating the devices or media
Definitions
- the present invention generally relates to the treatment of bursitis, i.e. a painful inflammation of a bursa which is a soft, fluid-filled sac that covers and cushions the relative movement between bones, tendons and muscles near the patient's joints.
- bursitis i.e. a painful inflammation of a bursa which is a soft, fluid-filled sac that covers and cushions the relative movement between bones, tendons and muscles near the patient's joints.
- the invention in particular concerns a device and method for treatment of bursitis in the human or animal body on permanent basis, i.e. a device and technique that destroys all bursa membrane cells that cause the inflammation.
- Bursitis is an unsolved medical problem. Bursitis is an inflammation of a bursa or protecting sac that is located in or near the patients joints. Bursitis can be acute resulting in a sudden, sharp pain following an injury, or it can be chronic as a result of a recurrent inflammation in the same area. Most commonly, bursitis is caused by trauma, infection and crystal deposits. Bursitis typically results from overuse or injury of a joint as a consequence of intensive working or playing, poor conditioning before exercising or sporting, systematic incorrect posture at work or rest, or an abnormal positioned joint as a result of for instance arthritis or bone length differences that stress soft tissue structures in the human or animal body. Bursitis exceptionally however may also appear in association with other diseases like rheumatoid arthritis, tuberculosis, psoriatic arthritis, gout, a bacterial infection, etc.
- bursitis usually occurs under shoulder muscles, at elbows (called epitrochlear bursitis), near the thigh or hip (called trochanteric bursitis), at heel bones (called retrocalcaneal bursitis) or kneecaps (called infrapatellar bursitis). It can also occur in the buttocks (called ischiogluteal bursitis).
- Anti-inflammatory medication used in the treatment of bursitis includes aspirin or non-steroidal drugs such as ibuprofen, naproxen or indomethacin. In case bursitis is the result of a bacterial infection, antibiotics can be used as well.
- An alternative treatment consists in aspiration or surgical drainage of fluid from the bursa, and the injection of corticosteroids in the bursa.
- the treatment with corticosteroids however must be dosed carefully because of the long list of potential side-effects of corticosteroids.
- a reservoir for holding the rinsing aid in fluid, freezing fluid or gaseous state
- a heat exchanger for controlling the temperature of the rinsing aid such that said temperature of said rinsing aid enables to destroy cells causing said inflammation
- a supply line coupled to the reservoir, for transporting the rinsing aid from the reservoir to the bursa
- an access device coupled to the supply line, for injecting the rinsing aid into the bursa
- the device according to the present invention enables to rinse or flush the bursa with a temperature controlled therapeutic rinsing fluid or gas, e.g. physiological water at 50.degree. C. or hot air, thereby destroying all bursa membrane cells causing the inflammation and removing the risk for recurrent or even chronic occurrence of the inflammation.
- a temperature controlled therapeutic rinsing fluid or gas e.g. physiological water at 50.degree. C. or hot air
- the temperature controlled therapeutic rinsing agent with caustic effect may stay a few minutes, e.g. 3 minutes, in the bursa during the so called “treatment phase”.
- the optimal rinsing duration for bursitis treatment using the device according to the present invention depends on the therapeutic fluid or gas used, the temperature thereof, the nature and degree of inflammation, and consequently has to be determined experimentally.
- the rinsing agent is removed via the drain tube during the so called “aspiration phase”.
- the supply line and drain tube for the rinsing aid may be integrated such that a single access device, e.g. a single needle or catheter can be used for the rinsing phase and aspiration phase. Alternatively, separate pipes and needles or catheters may be foreseen. It is further noticed that the supply line may be isolated.
- the reservoir may be a sac, a tank, a sterile fluid bag, etc.
- a sterile fluid bag is preferred because the therapeutic rinsing aid can be kept sterile therein.
- the heat exchanger may be located in or around the reservoir, or may be positioned in or along the supply line.
- the temperature must be controlled such that the temperature of the therapeutic fluid or gas in the bursa enables to destroy the bursa membrane cells causing the inflammation within an acceptable time interval of a few minutes.
- the logarithmic time-temperature curve at which irreversible cell necrosis occurs has been studied and published for skin treatment and may be used to select the temperature and time interval of bursitis treatment according to the present invention.
- the drain may consist of a redon or a drain tube and a receptacle such as a redon bottle that is carried a period of time by the patient.
- a drain for instance a redon or a catheter with a plurality of holes to extract the remaining fluid under vacuum, partial vacuum or sub-pressure generated via a pump.
- dry gas may be flushed through the bursa as part of this drying phase in order to remove the last droplets or vapour of the rinsing aid from the bursa.
- the drying phase will enhance the adhesion of top and bottom layer of the bursa.
- the access device in the bursitis treatment device may include one or more of the following, perforated or not:
- the above listed access devices can be separate or combined, adjacent or concentric.
- the catheters can be straight, bent or curled.
- the end of the curl can be attached to the needle or trocar by means of a wire.
- the catheters can be coated by an agent that improves sliding, such as Teflon.
- a radio-opaque wire can be incorporated in the catheter. Insertion of the access device preferably takes place under radiological control and/or ultrasound control.
- an injection needle a Veress needle, a catheter perforated with holes, or even a spray with nozzle.
- a Veress needle may be preferred because it is designed to avoid double perforation of the bursa.
- the spring and pestle which inherently form part of such a Veress needle will prevent a second perforation of the bursa wall once the tip of the Veress needle has entered the bursa.
- Plural needles or catheters may be foreseen depending on the attainable pressure and flow rate.
- a perforated catheter surrounding an injection needle is preferred as access device.
- the needle enables to inject the rinsing aid in the bursa
- the perforated catheter ensures complete removal of the rinsing aid after the treatment.
- Plural perforations in the catheter avoid blockage of the drain, even if one or a few perforations would become blocked as a result of tissue aggregation.
- the perforated catheter may be made of plastic or thermoplastic material or other material that can be sterilized for insertion in the body.
- the access device is supplemented with a device or piece that aspires moisture.
- This piece may also be useful when manually irrigating the bursa and verifying drainaige.
- the access device in the bursitis treatment device may include a guide.
- Such guide may assist in bringing the needle or catheter in the bursa.
- the access device in the bursitis treatment device may comprise one or more of the following:
- the optional temperature sensor, pressure sensor, flow sensor or a combination of sensors may be integrated in the needle or catheter that intrudes the bursa during the treatment.
- An advantage thereof is that the temperature in the bursa, pressure in the bursa, flow rate, or a combination thereof can be measured very accurately and can serve as input for controlling the reservoir temperature, the supply line temperature, the container pressure and/or the flow rate.
- a controller of these parameters that will be described further in this patent application may operate in an automated fashion on the basis of sensory input.
- the bursitis treatment device further includes:
- the bursitis treatment method according to the invention may be complemented with arthroscopic treatment using an inspection camera.
- inspection camera enables to visibly inspect the inside of the bursa which enables the physician or operator of the bursitis treatment device to inspect the correct location of the insertion device with respect to the bursa, to determine the size and extension of the bursa, to exclude extravasation and/or pre-existing connections to the joint space.
- the camera also enables to draw conclusions with respect to effectiveness of the treatment and eventual duration or repetition of the treatment process.
- a contrasting fluid may be used.
- the supply line and drain for injecting and removing a fluid into and from the bursa in the bursitis treatment device may be thermally isolated.
- the needle(s) or catheter(s) for injecting or removing the fluid may be isolated by for instance ceramic coating, plastic coating, or another isolation technique.
- a double-walled needle or access device with vacuum space between the two walls could be used. The objective thereof is to reduce the outside temperature, for instance by 5.degree. C., such that no damage is caused to the surrounding cells in the treatment period that may for instance last for 200 seconds.
- the needle or access device may further be supplemented with an isolating, preferably cone-shaped element that isolates the skin and eventually also tissue between the skin and bursa from direct contact with the access device that transports the heated rinsing aid.
- a cone shaped element is preferred to ease insertion, but alternate shapes may be considered as well for the isolating element.
- such isolating element is slidably mounted on the access device such that the injection depth of the access device remains controllable.
- the sliding isolating element may for instance be made out of rubber.
- the access device and drain in the bursitis treatment device are integrated into an insertion device comprising at least a first lumen for injection of the rinsing aid in the bursa and a second lumen for drainage of the rinsing aid, the second lumen being equipped with multiple drainage holes.
- injection and drainage of the rinsing aid may be combined in a single device.
- the plural holes guarantee continued drainage even when one or a few holes become obstructed through vessels or constituents in the drained fluid.
- Additional lumen may be integrated, e.g. to enable injection of additives.
- the plural lumen may be realized concentrically (e.g. a double wall or triple wall lumen), or may be realized side-by-side. Side-by-side lumen may be wrenched over the entire length or a tip portion, or may be spring-rotated in order to control the distance between successive drainage holes.
- the bursitis treatment device may comprise:
- a spectrometer for measuring colour fading of the wall of the bursa.
- the bursitis treatment device may be enabled to sense and analyse the colour spectrum and to measure as a result thereof the degree of non-viability of the bursa membrane cells inside the bursa. Again, this is useful information for controlling the duration of the treatment.
- the bursitis treatment device according to the invention may comprise:
- Such heat sensitive camera may be used to control the distribution of the rinsing aid and the coldest spot in the bursa such that non-viability of all bursa membrane cells that cause the inflammation is guaranteed.
- the rinsing aid may consist of:
- the bursitis treatment device may comprise:
- a second reservoir for holding a second rinsing aid in fluid, freezing fluid or gaseous state for pre-treatment of the bursa
- a third reservoir for holding a third rinsing aid in fluid, freezing fluid or gaseous state for post-treatment of the bursa.
- the bursa in an optional pre-treatment phase, can be rinsed with physiological water or gas or another neutral rinsing aid (e.g. salina) at a temperature between 0.degree. C. and 150.degree. C.
- physiological water or gas or another neutral rinsing aid e.g. salina
- the in- and outflow, working pressures and flow are optimised.
- the bursa is rinsed with for instance a pharmacologic active constituent in order to remove all caustic agents. Thereafter, a suction technique is applied in the so called “aspiration phase” to empty the bursa under vacuum, partial vacuum or sub-pressure.
- the bursitis treatment device further comprises means for controlling one or more of the following parameters:
- the bursitis treatment device may be fully programmable with respect to temperature, pressure, flow rate and run time.
- the control of temperature and pressure may be assisted by temperature sensors and pressure sensors as indicated here above Thanks to the controlled temperature, and the eventual killing nature of the rinsing aid, membrane cells on the inside of the bursa will be destroyed.
- the temperature, pressure, flow rate and time interval parameters for these phases of the treatment method may be controllable as well.
- the parameters may be adjustable through buttons, knobs, touch screens, etc. and hardware such as a heating element, a pump, a clock or timer integrated in the treatment device.
- the parameters may be controlled from a PC, terminal, remote control, etc. connected directly or via a network to a control interface of the bursitis treatment device.
- the needle or access device may be equipped with a valve, e.g. a thermostatic valve, and an electronic temperature sensor.
- the valve will remain closed as long as the temperature of the rinsing aid in the supply line stays below a desired, predefined temperature, and the rinsing aid shall be removed, e.g. towards a waste container for elimination.
- the valve will open as soon as the desired, set-point temperature of e.g. 60.degree. C. is reached. This way, the temperature where the bursa is exposed to shall describe a step function, which increases the effectiveness of the treatment.
- the fluid shall be prevented from entering the bursa and shall be guided towards a waste container for elimination. This enables for instance to deal with slow, gradual increase of the temperature due to lengthy supply lines, e.g. bridging several meters of distance between the reservoir and the access device
- Another option consists in a memory for storing one or more of the following:
- the measured parameter values such as reservoir, supply line or bursa temperature, reservoir or bursa pressure, flow rate, and duration of the different phases may be logged and stored in a data file.
- the preset target temperatures, pressures, flow rates and time intervals may be stored in such memory.
- the drain in the bursitis treatment device includes one or more of the following:
- the bursitis treatment device may include:
- the leakage detector serves as an instrument for quality control of the bursitis treatment device. If total inflow and total outflow are not equal, there might be a leakage with danger for the patient. In this case, the pump may be de-activated or the entire device may be de-activated automatically.
- the bursitis treatment device further optionally includes:
- the above mentioned data file may be ported to another device, e.g. a PC or network, via a wired or wireless data interface such as a Universal Serial Bus (USB), a Bluetooth interface, a WiFi interface, an Ethernet connection, etc.
- a wired or wireless data interface such as a Universal Serial Bus (USB), a Bluetooth interface, a WiFi interface, an Ethernet connection, etc.
- a corresponding bursitis treatment method as includes the steps of:
- the bursitis treatment method may include one or several of the following steps:
- pre-treatment of the bursa by injecting a second rinsing aid before injection of the rinsing aid;
- pre-treatment with a contrast agent enables to verify and inspect the correct location of the insertion device with respect to the bursa, determine the size and extension of the bursa, and exclude extravasation and/or pre-existing connections to the joint space.
- the pre-treatment rinsing phase enables to optimise the in- and outflow, working pressures and flow.
- the post-treatment rinsing phase removes all caustic agents.
- the bursitis treatment method may include one or several of the following steps:
- the bursitis treatment method may include the additional step of:
- the membrane walls of the bursa are stuck together.
- the present invention also concerns a corresponding cyst treatment device for treatment of a cyst in a patient
- the cyst treatment device may include:
- a reservoir for holding the rinsing aid in fluid, freezing fluid or gaseous state
- a heat exchanger for controlling the temperature of the rinsing aid such that the temperature of the rinsing aid enables to destroy cells of interlining of the cyst
- a supply line coupled to the reservoir, for transporting the rinsing aid from the reservoir to said cyst;
- an access device coupled to the supply line, for injecting the rinsing aid into said cyst
- a cyst is a closed sac consisting of a membrane filled with gaseous, fluids or semi-solid material. Such cyst can be treated by necrosis of cells of the interlining through the device according to the present invention.
- a bursitis treatment device for treatment of inflammation of a bursa in a patient includes:
- a reservoir for holding the rinsing aid in fluid, freezing fluid or gaseous state
- a supply line coupled to the reservoir, for transporting the rinsing aid from the reservoir to the balloon or sac;
- an access device coupled to the supply line, for injecting the rinsing aid into the balloon or sac;
- a heat exchanger for controlling the temperature of the rinsing aid such that a temperature of a wall of the balloon or sac enables to destroy cells
- a drain for removing the rinsing aid from the balloon or sac for elimination.
- the rinsing aid need not be directly in contact with the cells to be destroyed but may be injected in a balloon or sac that is first inserted in the patient's body to represents an artificial cyst therein.
- the temperature of the rinsing aid then is controlled in such a way that the temperature of the wall of the balloon or sac enables to destroy cells during the temperature treatment.
- the heat exchanger may be heating or cooling the rinsing aid, or may be able to perform both. Cooling may for instance be realized through use of liquid nitrogen, or through injection of chlorofluorocarbons (CFCs) that cool the wall of the balloon or sac through evaporation.
- CFCs chlorofluorocarbons
- the balloon or sac may for instance be provided around the catheter or access device for insertion in the patient's body.
- FIG. 1 illustrates a first embodiment of the bursitis treatment device according to the present invention
- FIG. 2 illustrates a second embodiment of the bursitis treatment device according to the present invention
- FIG. 3 illustrates the access device of an embodiment of the bursitis treatment device according to the present invention
- FIG. 4 is a detailed cross-section of the access device shown in FIG. 3 ;
- FIG. 5 is an IR image of a bursa that is therapeutically treated according to the method of the invention.
- FIG. 6 illustrates a preferred device for access/drainage
- FIG. 7 illustrates a variant embodiment of the preferred device for access/drainage
- FIG. 8 illustrates another variant embodiment of the preferred device for access/drainage.
- the bursitis treatment device 100 illustrated by FIG. 1 has one reservoir for a therapeutic fluid, 101 or RES, and a supply line 103 from the reservoir 101 to an access or insertion device in the bursa 150 .
- the bursitis treatment device 100 contains a pump 102 and a heat exchanger, 104 or HEAT EXCH, along the supply line 103 .
- a drain tube 105 with pump 106 extends from the bursa 150 .
- the supply line 103 and the drain tube 105 are supposed to be inserted in the bursa 150 through two separate access devices, i.e. two needles that are not shown in detail in FIG. 1 .
- FIG. 1 further shows a controller 107 , spectrometer 108 , cell counter 109 , chemical sensor 110 and valve 111 that may form part of the bursitis treatment device 100 .
- the reservoir 101 holds rinsing aid at ambient temperature.
- the reservoir 101 may be open but preferably is closed for reasons of sterility.
- the access devices are inserted in the bursa under radiological and/or ultrasound control. Thereafter, inner adhesions pre-existing in the bursa are breached in the insufflation phase during which the bursa is filled and expanded using carbondioxide or an alternate gas.
- a contrast agent is injected in the bursa to inspect the correct location of the insertion device with respect to the bursa, to determine the size and extension of the bursa, and to exclude extravasation and or pre-existing connections to the joint space.
- the in- and outflow, as well as the working pressures are optimised in a pre-treatment phase where the bursa is rinsed with neutral rinsing aid.
- the pump 102 transfers an active temperature controlled rinsing agent with caustic effect from the reservoir 101 to the bursa 150 in order to fill the bursa 150 with the therapeutic fluid.
- the rinsing agent is temperature controlled by the heat exchanger 104 , e.g. up to the desired temperature of 50.degree. C., such that temperature controlled rinsing agent is pumped into the bursa 150 .
- the bursa is rinsed with the temperature controlled rinsing aid for a desired time interval of about 3 minutes in order to hold the bursa for about 3 minutes at the desired temperature of 50.degree. C. thereby destroying the bursa membrane cells that cause the inflammation.
- Outflow is performed with the second pump 106 .
- the caustic agent is removed by rinsing the bursa with neutral rinsing aid.
- the first pump 102 is inactivated and only the second pump 106 remains activated to remove the remaining rinsing aid from the bursa 150 via drain 105 .
- biocompatible glue may be used to stick together the bursa membrane walls.
- the controller 107 controls the hardware in the bursitis treatment device 100 : it activates/de-activates the pumps 102 and 106 , it controls the flow rate in the supply line 103 , and it controls the heat exchanger 104 in order to obtain the desired temperature of 50.degree. C.
- the controller 107 may receive feedback from a temperature sensor in the supply line 103 or in the bursa 150 , and use the reported temperatures to control the heat exchanger 104 .
- the controller may also receive feedback from a pressure sensor in the bursa, from a flow sensor, or from a thermal camera to obtain more precise information on the temperature distribution in the bursa and more particularly along the membrane surface of the bursa.
- a sensor for cell particles in the drain tube 105 may provide input to the controller 107 enabling the controller 107 to stop the therapeutic treatment only when the fraction of cell particles has dropped below a certain threshold.
- an inspection camera may be provided for combined arthroscopy. The inspection camera may be integrated with the supply line 103 , may be integrated with the drain 105 , may be integrated with the access or insertion device, or may be brought into the bursa independently from the supply and drain. The feedback from such camera may also be used by the controller 107 to control the duration of the different phases. Further a leakage detector may provide information to the controller 107 enabling the latter to switch off the entire device 100 .
- a variant embodiment of the pump may consist of a cover holding a bag of physiologic water that is held under pressure via a hand-operated pressure bulb.
- the pressure may be indicated by a pressure indicator on the cover.
- FIG. 2 shows a variant embodiment 200 having two reservoirs, a first reservoir, 201 or RES 1 , with a heat exchanger 203 , and a second reservoir, 202 or RES 2 .
- a first supply line 204 couples the first reservoir 201 to a first intake of a switch, 206 or SWITCH IN.
- a second supply line 205 couples the second reservoir 202 to a second intake of the switch 206 .
- a third supply line 208 extends from the switch 206 to access device 209 .
- the burst treatment device 200 contains a first pump 207 .
- a drain 210 with second pump 211 extends from the access device 209 to a receptacle not shown in FIG. 2 .
- the bursa can be filled and expanded in a pre-treatment phase with physiological water, PHYS. H2O, kept at 20.degree. C. in the second reservoir 202 , without having to remove or replace reservoirs.
- a gas like carbondioxide or CO2 may be used in the pre-treatment phase. Such gas can be drained faster and enables to breach inner adhesions and completely open the bursa through inflation thereby preparing the bursa optimally for the therapeutic phase.
- the pre-treatment phase is stopped and the switch 206 is changed such that demineralised water kept at 50.degree. C. in the first reservoir 201 is now pumped into the bursa.
- the temperature controlled demineralised water will have a lethal effect on cells at the bursa surface that have caused the inflammation.
- the therapeutic temperature controlled demineralised water is injected in the bursa via access device 209 .
- Outflow is performed with the second pump 211 .
- the access device 209 will be described in more detail with reference to FIG. 3 and FIG. 4 . It serves as single insertion device during the different phases whereto both the inlet or supply line 208 and the outlet or drain tube 210 are coupled.
- the caustic agent is removed by rinsing the bursa with neutral rinsing aid.
- pump 207 becomes de-activated whereas pump 211 remains activated to start the aspiration phase.
- the fluid in the bursa is now drained via drain tube 210 .
- the bursa deflates and the bursa membrane claps together. Regeneration of the cells causing inflammation of the bursa is avoided which definitively resolves the bursitis.
- the bursa may be flushed with fluid at 37.degree. C. to avoid spreading of the water in the patient's body.
- the bursa is rinsed out to remove all caustic agents.
- a further optional step consists in the application of Tissuecol or another fibrin glue on the bursa surface.
- Tissuecol or another fibrin glue for an average size bursa, the application of for instance 0.5 ml biocompatible glue will suffice.
- the aim of the biocompatible glue is to stick together the membrane surfaces after the therapeutic treatment.
- the pre-treatment phase wherein the bursa is flushed with water or CO2 to breach pre-existing inner adhesions may be executed in a pulsated way: alternately the fluid or gas will be injected in the bursa via the needle and sucked away from the bursa via the needle.
- the pulsating pre-treatment has as advantage that obstruction of the needle as a result of fibrin or clotting of loose tissue in the bursa is avoided.
- FIG. 3 and FIG. 4 illustrate the access or insertion device 209 of FIG. 2 in more detail.
- the access device 209 has a needle 503 that is covered with a sheet 303 .
- the access device 209 has a redon 502 or catheter with plural perforations 508 through which the fluids or gasses are sucked away from the bursa.
- FIG. 3 and FIG. 4 also show the presence of a temperature sensor, 403 or TEMP, and a pressure sensor, 404 or PRES, that feed back the temperature and pressure measured in the bursa via wiring 309 .
- the supply line 208 is connected to a first inlet 304 of the needle 301 .
- An additional inlet 305 is foreseen for injecting for instance fluids in the bursa via the same access device 209 .
- the drain tube 210 is connected to the outlet of the redon 302 .
- FIG. 5 at last shows an IR image of a bursa 502 near a bone 501 that is therapeutically treated with temperature controlled demineralised water injected via a first access device 503 and drained via a second access device 504 .
- FIG. 5 illustrates very well the temperature distribution in the bursa. In order to destroy all cells causing inflammation of the bursa and avoid regeneration of the bursitis, it is important that the entire bursa surface is temperature controlled evenly. FIG. 5 illustrates that this is the case using the invented method.
- FIG. 6 and FIG. 7 show insertion devices that contain a first lumen, 601 or 701 , for injection of fluids and a second lumen, 602 or 702 , for drainage of fluids. Additional lumen may be included, e.g. to enable injection of additives.
- the lumen used for drainage, 602 or 702 is equipped with multiple drainage holes, 611 , 612 , 613 , 614 and 615 in FIG. 6 .
- the plural holes guarantee continued drainage even when one or a few holes become obstructed through vessels or constituents in the drained fluid.
- Lumen 602 may have a double wall 620 with vacuum space in between, a sliding, isolating element 630 and a camera 603 .
- the plural lumen may be realized concentrically as illustrated by FIG. 6 (e.g. a double wall or triple wall lumen), or may be realized side-by-side as illustrated by FIG. 7 .
- Side-by-side lumen may be wrenched over the entire length or a tip portion, as indicated by arrow 800 in FIG. 8 , or may be spring-rotated in order to control the distance between successive drainage holes.
- top”, bottom”, “over”, “under”, and the like are introduced for descriptive purposes and not necessarily to denote relative positions. It is to be understood that the terms so used are interchangeable under appropriate circumstances and embodiments of the invention are capable of operating according to the present invention in other sequences, or in orientations different from the one(s) described or illustrated above.
Abstract
A bursitis treatment device (100; 200) for treatment of inflammation of a bursa (150; 502) in a patient's joint includes: a rinsing aid; a reservoir (101; 201) for holding the rinsing aid in fluid, freezing fluid or gaseous state; a supply line (103; 204, 208) for transporting the rinsing aid; a heat exchanger (104; 203) for controlling the temperature of the rinsing aid—such that the temperature of the rinsing aid enables to destroy cells causing the inflammation; an access device (209) for injecting the rinsing aid into the bursa (150; 205); and a drain (105; 210) for removing the rinsing aid from the bursa (150; 205) for elimination.
Description
- This application is a divisional of U.S. application Ser. No. 13/575,028 filed Jul. 25, 2012, which is a National Stage Entry of PCT/EP11/00317 filed Jan. 26, 2011, claiming priority to European Application No. 10000758.2 filed Jan. 26, 2010, all of which are incorporated by reference in their entirety.
- The present invention generally relates to the treatment of bursitis, i.e. a painful inflammation of a bursa which is a soft, fluid-filled sac that covers and cushions the relative movement between bones, tendons and muscles near the patient's joints. The invention in particular concerns a device and method for treatment of bursitis in the human or animal body on permanent basis, i.e. a device and technique that destroys all bursa membrane cells that cause the inflammation.
- Bursitis is an unsolved medical problem. Bursitis is an inflammation of a bursa or protecting sac that is located in or near the patients joints. Bursitis can be acute resulting in a sudden, sharp pain following an injury, or it can be chronic as a result of a recurrent inflammation in the same area. Most commonly, bursitis is caused by trauma, infection and crystal deposits. Bursitis typically results from overuse or injury of a joint as a consequence of intensive working or playing, poor conditioning before exercising or sporting, systematic incorrect posture at work or rest, or an abnormal positioned joint as a result of for instance arthritis or bone length differences that stress soft tissue structures in the human or animal body. Bursitis exceptionally however may also appear in association with other diseases like rheumatoid arthritis, tuberculosis, psoriatic arthritis, gout, a bacterial infection, etc.
- When the joint is overused or when it stays under pressure or tension for extended periods of time, a nearby bursa or sac can become inflamed. The bursa then fills with excess fluid causing additional pressure on surrounding tissue resulting in bursitis. Bursitis usually occurs under shoulder muscles, at elbows (called epitrochlear bursitis), near the thigh or hip (called trochanteric bursitis), at heel bones (called retrocalcaneal bursitis) or kneecaps (called infrapatellar bursitis). It can also occur in the buttocks (called ischiogluteal bursitis).
- Existing methods for treatment of bursitis include rest, physical therapy, protecting the inflamed area, use of anti-inflammatory drugs, surgical drainage, injection of corticosteroids and surgical removal of the bursa. An overview of state of the art treatment methods for bursitis is given in the article “Greater Trochanteric Pain Syndrome: A Review of Anatomy, Diagnosis and Treatment” from the authors Bryan S. Williams and Steven P. Cohen, published in “Anesthesia & Analgesia”, Vol. 108, No. 5, May 2009, pages 1662-1670. The known bursitis treatment methods however all remove or suppress the inflammation only temporarily. Typically, the bursa grows back and the inflammation of the bursa re-appears after a few months.
- Resting, physical therapy and/or treating a bursa close to the skin with padding can relieve the patients discomfort and inflammation resulting from bursitis in seven to fourteen days. Preventive measures such as the use of cushioned chairs or protective gear near joints, warm-up and cool-down exercises, avoiding overuse of joints through sports or labour, and strengthening the muscles may further help the patient in avoiding or delaying re-appearance of the bursa inflammation.
- Anti-inflammatory medication used in the treatment of bursitis includes aspirin or non-steroidal drugs such as ibuprofen, naproxen or indomethacin. In case bursitis is the result of a bacterial infection, antibiotics can be used as well.
- An alternative treatment consists in aspiration or surgical drainage of fluid from the bursa, and the injection of corticosteroids in the bursa. The treatment with corticosteroids however must be dosed carefully because of the long list of potential side-effects of corticosteroids.
- In case of chronic bursitis that cannot be treated in the conservative way, invasive surgical removal of the bursa will be considered.
- It is an objective of the present invention to disclose a device and method for the treatment of bursitis that overcomes the drawbacks and shortcomings mentioned here above in relation to the existing bursitis treatment methods. In particular, it is an objective of the present invention to disclose a device and method that enable to treat bursitis permanently, thereby avoiding recurrent appearance of the bursa inflammation.
- The above defined objective is realized and the prior art shortcomings are overcome by a bursitis treatment device including:
- a rinsing aid;
- a reservoir for holding the rinsing aid in fluid, freezing fluid or gaseous state;
- a heat exchanger for controlling the temperature of the rinsing aid such that said temperature of said rinsing aid enables to destroy cells causing said inflammation;
- a supply line, coupled to the reservoir, for transporting the rinsing aid from the reservoir to the bursa;
- an access device, coupled to the supply line, for injecting the rinsing aid into the bursa; and
- a drain for removing the rinsing aid from the bursa for elimination.
- Thus, the device according to the present invention enables to rinse or flush the bursa with a temperature controlled therapeutic rinsing fluid or gas, e.g. physiological water at 50.degree. C. or hot air, thereby destroying all bursa membrane cells causing the inflammation and removing the risk for recurrent or even chronic occurrence of the inflammation. The temperature controlled therapeutic rinsing agent with caustic effect may stay a few minutes, e.g. 3 minutes, in the bursa during the so called “treatment phase”. The optimal rinsing duration for bursitis treatment using the device according to the present invention depends on the therapeutic fluid or gas used, the temperature thereof, the nature and degree of inflammation, and consequently has to be determined experimentally. Thereafter, the rinsing agent is removed via the drain tube during the so called “aspiration phase”.
- It is noticed that the supply line and drain tube for the rinsing aid may be integrated such that a single access device, e.g. a single needle or catheter can be used for the rinsing phase and aspiration phase. Alternatively, separate pipes and needles or catheters may be foreseen. It is further noticed that the supply line may be isolated.
- The reservoir may be a sac, a tank, a sterile fluid bag, etc. The use of a sterile fluid bag is preferred because the therapeutic rinsing aid can be kept sterile therein.
- The heat exchanger may be located in or around the reservoir, or may be positioned in or along the supply line. The temperature must be controlled such that the temperature of the therapeutic fluid or gas in the bursa enables to destroy the bursa membrane cells causing the inflammation within an acceptable time interval of a few minutes. The logarithmic time-temperature curve at which irreversible cell necrosis occurs has been studied and published for skin treatment and may be used to select the temperature and time interval of bursitis treatment according to the present invention.
- The drain may consist of a redon or a drain tube and a receptacle such as a redon bottle that is carried a period of time by the patient. Thus, after having treated the bursa with the temperature controlled therapeutic rinsing aid, the remaining rinsing fluid is eliminated from the bursa via a drain, for instance a redon or a catheter with a plurality of holes to extract the remaining fluid under vacuum, partial vacuum or sub-pressure generated via a pump. Eventually, dry gas may be flushed through the bursa as part of this drying phase in order to remove the last droplets or vapour of the rinsing aid from the bursa. The drying phase will enhance the adhesion of top and bottom layer of the bursa.
- Optionally, the access device in the bursitis treatment device may include one or more of the following, perforated or not:
- a needle;
- a trocar;
- a Veress needle;
- a catheter;
- a spray; and
- a nozzle.
- The above listed access devices can be separate or combined, adjacent or concentric. The catheters can be straight, bent or curled. The end of the curl can be attached to the needle or trocar by means of a wire. The catheters can be coated by an agent that improves sliding, such as Teflon. A radio-opaque wire can be incorporated in the catheter. Insertion of the access device preferably takes place under radiological control and/or ultrasound control.
- Depending on the state of the rinsing aid—fluid or gas—and its temperature, it may be advantageous to use an injection needle, a Veress needle, a catheter perforated with holes, or even a spray with nozzle. Any of these implementations will have to be cusped for intrusion in the human or animal body and for puncturing the bursa wall. A Veress needle may be preferred because it is designed to avoid double perforation of the bursa. The spring and pestle which inherently form part of such a Veress needle will prevent a second perforation of the bursa wall once the tip of the Veress needle has entered the bursa. Plural needles or catheters may be foreseen depending on the attainable pressure and flow rate.
- In general, tests have demonstrated that for the application of bursitis treatment according to the current invention, a perforated catheter surrounding an injection needle is preferred as access device. Whereas the needle enables to inject the rinsing aid in the bursa, the perforated catheter ensures complete removal of the rinsing aid after the treatment. Plural perforations in the catheter avoid blockage of the drain, even if one or a few perforations would become blocked as a result of tissue aggregation. The perforated catheter may be made of plastic or thermoplastic material or other material that can be sterilized for insertion in the body.
- Advantageously, the access device is supplemented with a device or piece that aspires moisture. This piece may also be useful when manually irrigating the bursa and verifying drainaige.
- Optionally, the access device in the bursitis treatment device may include a guide.
- Such guide may assist in bringing the needle or catheter in the bursa.
- Further optionally, the access device in the bursitis treatment device may comprise one or more of the following:
- a temperature sensor;
- a pressure sensor; and
- a flow sensor.
- The optional temperature sensor, pressure sensor, flow sensor or a combination of sensors may be integrated in the needle or catheter that intrudes the bursa during the treatment. An advantage thereof is that the temperature in the bursa, pressure in the bursa, flow rate, or a combination thereof can be measured very accurately and can serve as input for controlling the reservoir temperature, the supply line temperature, the container pressure and/or the flow rate. A controller of these parameters that will be described further in this patent application may operate in an automated fashion on the basis of sensory input.
- According to another optional aspect, the bursitis treatment device further includes:
- a camera mounted on the syringe.
- Thus, the bursitis treatment method according to the invention may be complemented with arthroscopic treatment using an inspection camera. Such inspection camera enables to visibly inspect the inside of the bursa which enables the physician or operator of the bursitis treatment device to inspect the correct location of the insertion device with respect to the bursa, to determine the size and extension of the bursa, to exclude extravasation and/or pre-existing connections to the joint space. After the treatment, the camera also enables to draw conclusions with respect to effectiveness of the treatment and eventual duration or repetition of the treatment process. In order to better visualize eventual fistula, a contrasting fluid may be used.
- The supply line and drain for injecting and removing a fluid into and from the bursa in the bursitis treatment device may be thermally isolated.
- The needle(s) or catheter(s) for injecting or removing the fluid may be isolated by for instance ceramic coating, plastic coating, or another isolation technique. Alternatively, a double-walled needle or access device with vacuum space between the two walls could be used. The objective thereof is to reduce the outside temperature, for instance by 5.degree. C., such that no damage is caused to the surrounding cells in the treatment period that may for instance last for 200 seconds. To avoid burning the patient's skin, the needle or access device may further be supplemented with an isolating, preferably cone-shaped element that isolates the skin and eventually also tissue between the skin and bursa from direct contact with the access device that transports the heated rinsing aid. A cone shaped element is preferred to ease insertion, but alternate shapes may be considered as well for the isolating element. Preferably, such isolating element is slidably mounted on the access device such that the injection depth of the access device remains controllable. The sliding isolating element may for instance be made out of rubber.
- Advantageously, the access device and drain in the bursitis treatment device are integrated into an insertion device comprising at least a first lumen for injection of the rinsing aid in the bursa and a second lumen for drainage of the rinsing aid, the second lumen being equipped with multiple drainage holes.
- Indeed, injection and drainage of the rinsing aid may be combined in a single device. The plural holes guarantee continued drainage even when one or a few holes become obstructed through vessels or constituents in the drained fluid. Additional lumen may be integrated, e.g. to enable injection of additives. The plural lumen may be realized concentrically (e.g. a double wall or triple wall lumen), or may be realized side-by-side. Side-by-side lumen may be wrenched over the entire length or a tip portion, or may be spring-rotated in order to control the distance between successive drainage holes.
- Still optionally, the bursitis treatment device may comprise:
- a spectrometer for measuring colour fading of the wall of the bursa.
- Through a colorimeter or spectrometer that for instance projects light in the bursa via the needle or catheter, and that guides the reflected light via the same needle or catheter onto a sensor, the bursitis treatment device may be enabled to sense and analyse the colour spectrum and to measure as a result thereof the degree of non-viability of the bursa membrane cells inside the bursa. Again, this is useful information for controlling the duration of the treatment.
- Optionally, the bursitis treatment device according to the invention may comprise:
- a heat sensitive camera.
- Such heat sensitive camera may be used to control the distribution of the rinsing aid and the coldest spot in the bursa such that non-viability of all bursa membrane cells that cause the inflammation is guaranteed.
- The rinsing aid may consist of:
- a hypertonic saline;
- an alcohol;
- acetic acid;
- steam;
- demineralised water; or
- another caustic agent.
- Obviously, alternative products or solutions may be excellent rinsing aids with caustic effect for use in the bursitis treatment device according to the invention. The skilled person will appreciate that the inventive nature of the device does not lie in the use of a particular rinsing aid and it is consequently not the intention to restrict applicability of the invention to any particular choice of rinsing aid.
- Further optionally, the bursitis treatment device may comprise:
- a second reservoir for holding a second rinsing aid in fluid, freezing fluid or gaseous state for pre-treatment of the bursa; and/or
- a third reservoir for holding a third rinsing aid in fluid, freezing fluid or gaseous state for post-treatment of the bursa.
- Thus, in an optional pre-treatment phase, the bursa can be rinsed with physiological water or gas or another neutral rinsing aid (e.g. salina) at a temperature between 0.degree. C. and 150.degree. C. As a result of the pre-treatment phase, the in- and outflow, working pressures and flow are optimised.
- In an optional post-treatment phase, the bursa is rinsed with for instance a pharmacologic active constituent in order to remove all caustic agents. Thereafter, a suction technique is applied in the so called “aspiration phase” to empty the bursa under vacuum, partial vacuum or sub-pressure.
- Optionally, the bursitis treatment device further comprises means for controlling one or more of the following parameters:
- temperature in the supply line;
- temperature in the reservoir;
- temperature in the bursa;
- temperature in the outflow line;
- pressure in the reservoir;
- pressure in the supply line;
- pressure in the bursa;
- pressure in the outflow line;
- flow rate of the rinsing aid; and
- time interval for injecting the rinsing aid.
- In other words, the bursitis treatment device according to the invention may be fully programmable with respect to temperature, pressure, flow rate and run time. The control of temperature and pressure may be assisted by temperature sensors and pressure sensors as indicated here above Thanks to the controlled temperature, and the eventual killing nature of the rinsing aid, membrane cells on the inside of the bursa will be destroyed. In case of pre-treatment and/or post-treatment phase, the temperature, pressure, flow rate and time interval parameters for these phases of the treatment method may be controllable as well. The parameters may be adjustable through buttons, knobs, touch screens, etc. and hardware such as a heating element, a pump, a clock or timer integrated in the treatment device. Alternatively, the parameters may be controlled from a PC, terminal, remote control, etc. connected directly or via a network to a control interface of the bursitis treatment device.
- In order to control the temperature of the rinsing aid such that the temperature of the fluid injected in the bursa changes to the desired heating temperature abruptly, the needle or access device may be equipped with a valve, e.g. a thermostatic valve, and an electronic temperature sensor. The valve will remain closed as long as the temperature of the rinsing aid in the supply line stays below a desired, predefined temperature, and the rinsing aid shall be removed, e.g. towards a waste container for elimination. The valve will open as soon as the desired, set-point temperature of e.g. 60.degree. C. is reached. This way, the temperature where the bursa is exposed to shall describe a step function, which increases the effectiveness of the treatment. As long as the temperature of the rinsing aid is below the desired temperature, the fluid shall be prevented from entering the bursa and shall be guided towards a waste container for elimination. This enables for instance to deal with slow, gradual increase of the temperature due to lengthy supply lines, e.g. bridging several meters of distance between the reservoir and the access device
- Another option consists in a memory for storing one or more of the following:
- preset and/or measured temperature values;
- preset and/or measured pressure values;
- preset and/or measured flow rate values; and
- preset and/or measured time interval values.
- Thus, the measured parameter values such as reservoir, supply line or bursa temperature, reservoir or bursa pressure, flow rate, and duration of the different phases may be logged and stored in a data file. Also the preset target temperatures, pressures, flow rates and time intervals may be stored in such memory.
- Optionally, the drain in the bursitis treatment device includes one or more of the following:
- a cell counter; and
- a chemical sensor for detection of cell constituents.
- This way, it becomes possible to detect when the number or density of cell constituents has dropped below a certain threshold, and this information may serve as input to control the duration of the treatment.
- Also optionally, the bursitis treatment device may include:
- a leakage detector.
- The leakage detector serves as an instrument for quality control of the bursitis treatment device. If total inflow and total outflow are not equal, there might be a leakage with danger for the patient. In this case, the pump may be de-activated or the entire device may be de-activated automatically.
- The bursitis treatment device further optionally includes:
- a data interface.
- Hence, the above mentioned data file may be ported to another device, e.g. a PC or network, via a wired or wireless data interface such as a Universal Serial Bus (USB), a Bluetooth interface, a WiFi interface, an Ethernet connection, etc.
- A corresponding bursitis treatment method as includes the steps of:
- insertion of an access device in the bursa;
- injecting via a supply line, coupled between a reservoir and the access device, a temperature controlled rinsing aid into the bursa;
- controlling the temperature of the rinsing aid such that the temperature of the rinsing aid enables to destroy cells causing the inflammation; and
- removing via a drain the rinsing aid from the bursa for elimination.
- Optionally, the bursitis treatment method may include one or several of the following steps:
- insufflating the bursa thereby breaching inner adhesions;
- imaging of the bursa with radio-opaque contrast medium;
- pre-treatment of the bursa by injecting a second rinsing aid before injection of the rinsing aid; and/or
- post-treatment of the bursa by injecting a third rinsing.
- Whereas insufflating enables to breach pre-existing inner adhesions, pre-treatment with a contrast agent enables to verify and inspect the correct location of the insertion device with respect to the bursa, determine the size and extension of the bursa, and exclude extravasation and/or pre-existing connections to the joint space. The pre-treatment rinsing phase enables to optimise the in- and outflow, working pressures and flow. The post-treatment rinsing phase removes all caustic agents.
- Optionally, the bursitis treatment method may include one or several of the following steps:
- electrically charging the bursa.
- Electrically charging the bursa, enables to deposit certain active constituents on the wall of the bursa during the treatment.
- Further optionally, the bursitis treatment method may include the additional step of:
- gluing membrane surfaces of the bursa using a biocompatible glue.
- In the optional gluing phase, the membrane walls of the bursa are stuck together.
- In addition to a bursitis treatment, the present invention also concerns a corresponding cyst treatment device for treatment of a cyst in a patient, the cyst treatment device may include:
- a rinsing aid;
- a reservoir for holding the rinsing aid in fluid, freezing fluid or gaseous state;
- a heat exchanger for controlling the temperature of the rinsing aid such that the temperature of the rinsing aid enables to destroy cells of interlining of the cyst;
- a supply line, coupled to the reservoir, for transporting the rinsing aid from the reservoir to said cyst;
- an access device, coupled to the supply line, for injecting the rinsing aid into said cyst; and
- a drain for removing the rinsing aid from the cyst for elimination.
- Indeed, a cyst is a closed sac consisting of a membrane filled with gaseous, fluids or semi-solid material. Such cyst can be treated by necrosis of cells of the interlining through the device according to the present invention.
- Furthermore, a bursitis treatment device for treatment of inflammation of a bursa in a patient includes:
- means for inserting a balloon or sac in the bursa;
- a rinsing aid;
- a reservoir for holding the rinsing aid in fluid, freezing fluid or gaseous state;
- a supply line, coupled to the reservoir, for transporting the rinsing aid from the reservoir to the balloon or sac;
- an access device, coupled to the supply line, for injecting the rinsing aid into the balloon or sac;
- a heat exchanger for controlling the temperature of the rinsing aid such that a temperature of a wall of the balloon or sac enables to destroy cells; and
- a drain for removing the rinsing aid from the balloon or sac for elimination.
- Indeed, the rinsing aid need not be directly in contact with the cells to be destroyed but may be injected in a balloon or sac that is first inserted in the patient's body to represents an artificial cyst therein. The temperature of the rinsing aid then is controlled in such a way that the temperature of the wall of the balloon or sac enables to destroy cells during the temperature treatment.
- The heat exchanger may be heating or cooling the rinsing aid, or may be able to perform both. Cooling may for instance be realized through use of liquid nitrogen, or through injection of chlorofluorocarbons (CFCs) that cool the wall of the balloon or sac through evaporation.
- It is further noticed that the balloon or sac may for instance be provided around the catheter or access device for insertion in the patient's body.
-
FIG. 1 illustrates a first embodiment of the bursitis treatment device according to the present invention; -
FIG. 2 illustrates a second embodiment of the bursitis treatment device according to the present invention; -
FIG. 3 illustrates the access device of an embodiment of the bursitis treatment device according to the present invention; -
FIG. 4 is a detailed cross-section of the access device shown inFIG. 3 ; -
FIG. 5 is an IR image of a bursa that is therapeutically treated according to the method of the invention; -
FIG. 6 illustrates a preferred device for access/drainage; -
FIG. 7 illustrates a variant embodiment of the preferred device for access/drainage; and -
FIG. 8 illustrates another variant embodiment of the preferred device for access/drainage. - The
bursitis treatment device 100 illustrated byFIG. 1 has one reservoir for a therapeutic fluid, 101 or RES, and asupply line 103 from thereservoir 101 to an access or insertion device in thebursa 150. Thebursitis treatment device 100 contains apump 102 and a heat exchanger, 104 or HEAT EXCH, along thesupply line 103. Adrain tube 105 withpump 106 extends from thebursa 150. Thesupply line 103 and thedrain tube 105 are supposed to be inserted in thebursa 150 through two separate access devices, i.e. two needles that are not shown in detail inFIG. 1 .FIG. 1 further shows acontroller 107,spectrometer 108,cell counter 109,chemical sensor 110 andvalve 111 that may form part of thebursitis treatment device 100. - The
reservoir 101 holds rinsing aid at ambient temperature. Thereservoir 101 may be open but preferably is closed for reasons of sterility. In the insertion phase, the access devices are inserted in the bursa under radiological and/or ultrasound control. Thereafter, inner adhesions pre-existing in the bursa are breached in the insufflation phase during which the bursa is filled and expanded using carbondioxide or an alternate gas. In the verification phase, a contrast agent is injected in the bursa to inspect the correct location of the insertion device with respect to the bursa, to determine the size and extension of the bursa, and to exclude extravasation and or pre-existing connections to the joint space. The in- and outflow, as well as the working pressures are optimised in a pre-treatment phase where the bursa is rinsed with neutral rinsing aid. In the treatment phase, thepump 102 transfers an active temperature controlled rinsing agent with caustic effect from thereservoir 101 to thebursa 150 in order to fill thebursa 150 with the therapeutic fluid. Along thesupply line 103, the rinsing agent is temperature controlled by theheat exchanger 104, e.g. up to the desired temperature of 50.degree. C., such that temperature controlled rinsing agent is pumped into thebursa 150. The bursa is rinsed with the temperature controlled rinsing aid for a desired time interval of about 3 minutes in order to hold the bursa for about 3 minutes at the desired temperature of 50.degree. C. thereby destroying the bursa membrane cells that cause the inflammation. Outflow is performed with thesecond pump 106. Thereafter, in the so-called post-treatment phase, the caustic agent is removed by rinsing the bursa with neutral rinsing aid. Thereafter, in the so-called aspiration phase, thefirst pump 102 is inactivated and only thesecond pump 106 remains activated to remove the remaining rinsing aid from thebursa 150 viadrain 105. Eventually, biocompatible glue may be used to stick together the bursa membrane walls. - The
controller 107 controls the hardware in the bursitis treatment device 100: it activates/de-activates thepumps supply line 103, and it controls theheat exchanger 104 in order to obtain the desired temperature of 50.degree. C. Thecontroller 107 may receive feedback from a temperature sensor in thesupply line 103 or in thebursa 150, and use the reported temperatures to control theheat exchanger 104. The controller may also receive feedback from a pressure sensor in the bursa, from a flow sensor, or from a thermal camera to obtain more precise information on the temperature distribution in the bursa and more particularly along the membrane surface of the bursa. This information will enable the controller to more adequately control the flow rate and temperature of the rinsing aid, and to control the time interval for the different phases of the treatment. A sensor for cell particles in thedrain tube 105 may provide input to thecontroller 107 enabling thecontroller 107 to stop the therapeutic treatment only when the fraction of cell particles has dropped below a certain threshold. Alternatively, an inspection camera may be provided for combined arthroscopy. The inspection camera may be integrated with thesupply line 103, may be integrated with thedrain 105, may be integrated with the access or insertion device, or may be brought into the bursa independently from the supply and drain. The feedback from such camera may also be used by thecontroller 107 to control the duration of the different phases. Further a leakage detector may provide information to thecontroller 107 enabling the latter to switch off theentire device 100. - Whereas the pump 12 is drawn in the
supply line 103, a variant embodiment of the pump may consist of a cover holding a bag of physiologic water that is held under pressure via a hand-operated pressure bulb. In this embodiment of the pump, the pressure may be indicated by a pressure indicator on the cover. -
FIG. 2 shows avariant embodiment 200 having two reservoirs, a first reservoir, 201 or RES1, with aheat exchanger 203, and a second reservoir, 202 or RES2. Afirst supply line 204 couples thefirst reservoir 201 to a first intake of a switch, 206 or SWITCH IN. Similarly, asecond supply line 205 couples thesecond reservoir 202 to a second intake of theswitch 206. Athird supply line 208 extends from theswitch 206 to accessdevice 209. Along thisthird supply line 208, theburst treatment device 200 contains afirst pump 207. Adrain 210 with second pump 211 extends from theaccess device 209 to a receptacle not shown inFIG. 2 . - Thanks to the
second reservoir 202 and the manual orautomatic switch 206, the bursa can be filled and expanded in a pre-treatment phase with physiological water, PHYS. H2O, kept at 20.degree. C. in thesecond reservoir 202, without having to remove or replace reservoirs. Alternatively, a gas like carbondioxide or CO2 may be used in the pre-treatment phase. Such gas can be drained faster and enables to breach inner adhesions and completely open the bursa through inflation thereby preparing the bursa optimally for the therapeutic phase. After a few minutes, the pre-treatment phase is stopped and theswitch 206 is changed such that demineralised water kept at 50.degree. C. in thefirst reservoir 201 is now pumped into the bursa. In this therapeutic treatment phase, the temperature controlled demineralised water will have a lethal effect on cells at the bursa surface that have caused the inflammation. Just like the rinsing fluid or CO2 gas, the therapeutic temperature controlled demineralised water is injected in the bursa viaaccess device 209. Outflow is performed with the second pump 211. Here below, theaccess device 209 will be described in more detail with reference toFIG. 3 andFIG. 4 . It serves as single insertion device during the different phases whereto both the inlet orsupply line 208 and the outlet ordrain tube 210 are coupled. After the therapeutic phase, the caustic agent is removed by rinsing the bursa with neutral rinsing aid. Thereafter, pump 207 becomes de-activated whereas pump 211 remains activated to start the aspiration phase. The fluid in the bursa is now drained viadrain tube 210. As a result, the bursa deflates and the bursa membrane claps together. Regeneration of the cells causing inflammation of the bursa is avoided which definitively resolves the bursitis. - In an optional additional phase, the bursa may be flushed with fluid at 37.degree. C. to avoid spreading of the water in the patient's body. In other words, in the post-treatment phase the bursa is rinsed out to remove all caustic agents.
- A further optional step consists in the application of Tissuecol or another fibrin glue on the bursa surface. For an average size bursa, the application of for instance 0.5 ml biocompatible glue will suffice. The aim of the biocompatible glue is to stick together the membrane surfaces after the therapeutic treatment.
- It is noticed that the pre-treatment phase wherein the bursa is flushed with water or CO2 to breach pre-existing inner adhesions may be executed in a pulsated way: alternately the fluid or gas will be injected in the bursa via the needle and sucked away from the bursa via the needle. The pulsating pre-treatment has as advantage that obstruction of the needle as a result of fibrin or clotting of loose tissue in the bursa is avoided.
-
FIG. 3 andFIG. 4 illustrate the access orinsertion device 209 ofFIG. 2 in more detail. Theaccess device 209 has aneedle 503 that is covered with asheet 303. Within theneedle 301, theaccess device 209 has aredon 502 or catheter with plural perforations 508 through which the fluids or gasses are sucked away from the bursa.FIG. 3 andFIG. 4 also show the presence of a temperature sensor, 403 or TEMP, and a pressure sensor, 404 or PRES, that feed back the temperature and pressure measured in the bursa viawiring 309. Thesupply line 208 is connected to afirst inlet 304 of theneedle 301. Anadditional inlet 305 is foreseen for injecting for instance fluids in the bursa via thesame access device 209. To the outlet of theredon 302, thedrain tube 210 is connected. -
FIG. 5 at last shows an IR image of abursa 502 near abone 501 that is therapeutically treated with temperature controlled demineralised water injected via afirst access device 503 and drained via asecond access device 504. When interpreted together with the temperature scale on the rightmost side of the figure,FIG. 5 illustrates very well the temperature distribution in the bursa. In order to destroy all cells causing inflammation of the bursa and avoid regeneration of the bursitis, it is important that the entire bursa surface is temperature controlled evenly.FIG. 5 illustrates that this is the case using the invented method. -
FIG. 6 andFIG. 7 show insertion devices that contain a first lumen, 601 or 701, for injection of fluids and a second lumen, 602 or 702, for drainage of fluids. Additional lumen may be included, e.g. to enable injection of additives. The lumen used for drainage, 602 or 702, is equipped with multiple drainage holes, 611, 612, 613, 614 and 615 inFIG. 6 . The plural holes guarantee continued drainage even when one or a few holes become obstructed through vessels or constituents in the drained fluid.Lumen 602 may have adouble wall 620 with vacuum space in between, a sliding, isolatingelement 630 and acamera 603. - The plural lumen may be realized concentrically as illustrated by
FIG. 6 (e.g. a double wall or triple wall lumen), or may be realized side-by-side as illustrated byFIG. 7 . Side-by-side lumen may be wrenched over the entire length or a tip portion, as indicated byarrow 800 inFIG. 8 , or may be spring-rotated in order to control the distance between successive drainage holes. - Although the present invention has been illustrated by reference to specific embodiments, it will be apparent to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied with various changes and modifications without departing from the scope thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. In other words, it is contemplated to cover any and all modifications, variations or equivalents that fall within the scope of the basic underlying principles and whose essential attributes are claimed in this patent application. It will furthermore be understood by the reader of this patent application that the words “comprising” or “comprise” do not exclude other elements or steps, that the words “a” or “an” do not exclude a plurality, and that a single element, such as a computer system, a processor, or another integrated unit may fulfil the functions of several means recited in the claims. Any reference signs in the claims shall not be construed as limiting the respective claims concerned. The terms “first”, “second”, third”, “a”, “b”, “c”, and the like, when used in the description or in the claims are introduced to distinguish between similar elements or steps and are not necessarily describing a sequential or chronological order. Similarly, the terms “top”, “bottom”, “over”, “under”, and the like are introduced for descriptive purposes and not necessarily to denote relative positions. It is to be understood that the terms so used are interchangeable under appropriate circumstances and embodiments of the invention are capable of operating according to the present invention in other sequences, or in orientations different from the one(s) described or illustrated above.
Claims (21)
1. A bursitis treatment method for treatment of inflammation of a bursa in a patient's joint, said bursitis treatment method comprising the steps of:
penetrating the patient's skin, underlying tissue, and bursa wall with an access device to insert the access device in the bursa;
injecting via a supply line, coupled between a reservoir and said access device, a temperature controlled rinsing aid into the bursa;
controlling the temperature of said rinsing aid such that said temperature of said rinsing aid destroys bursa cells causing the inflammation within an acceptable time interval of a few minutes; and
removing via a drain said rinsing aid from the bursa for elimination.
2. A bursitis treatment method according to claim 1 , further comprising the step of:
at least one of a) pre-treating the bursa by injecting a second rinsing aid before injection of said rinsing aid to optimize working pressures, and b) post-treating the bursa by injecting a third rinsing aid to remove the rinsing aid from the bursa.
3. A bursitis treatment method according to claim 1 , further comprising the step of:
electrically charging the bursa to deposit active constituents on the wall of the bursa.
4. A bursitis treatment method according to claim 1 , further comprising the step of:
gluing membrane surfaces of the bursa using a biocompatible glue.
5. A bursitis treatment method according to claim 1 , further comprising the step of:
thermally isolating the supply line, access device, and drain.
6. A bursitis treatment method according to claim 1 , further comprising the steps of:
controlling temperature in said supply line;
controlling temperature in said reservoir;
controlling temperature in the bursa;
controlling temperature in an outflow line of said drain;
controlling pressure in said reservoir;
controlling pressure in said supply line;
controlling pressure in the bursa;
controlling pressure in an outflow line of said drain;
controlling flow rate of said rinsing aid; and
controlling a time interval for injecting said rinsing aid.
7. A bursitis treatment method according to claim 1 , further comprising the step of:
opening a thermally controlled valve in said supply line or said access device as soon as said rinsing aid in said supply line has reached a predefined temperature.
8. A bursitis treatment method according to claim 1 , wherein all the rinsing aid is removed from the bursa after the rinsing aid has been maintained within the bursa at said temperature for 200 seconds.
9. A bursitis treatment method according to claim 1 , wherein all the rinsing aid is removed from the bursa after the rinsing aid has been maintained within the bursa at said temperature for three minutes.
10. A bursitis treatment method according to claim 1 , wherein said temperature is 50° C.
11. A bursitis treatment method according to claim 1 , wherein said temperature is 60° C.
12. A bursitis treatment method according to claim 1 , wherein said rinsing aid is air.
13. A bursitis treatment method according to claim 1 , further comprising the step of:
injecting dry gas to remove last droplets or vapor of said rinsing aid from the bursa.
14. A bursitis treatment method according to claim 1 , further comprising the step of:
emptying the bursa by applying vacuum, partial vacuum or sub-pressure.
15. A bursitis treatment method according to claim 1 , further comprising the step of:
prior to injecting, preventing said rinsing aid from entering the bursa and guiding said rinsing aid towards a waste container for elimination until the rinsing aid reaches said temperature, and opening a valve to begin the injecting after the rinsing aid reached said temperature.
16. A bursitis treatment method according to claim 1 , further comprising the step of:
detecting a number and/or density of cell constituents in the drain;
wherein all the rinsing aid is removed from the bursa after the number and/or density of cell constituents has dropped below a certain threshold.
17. A bursitis treatment method according to claim 1 , further comprising the step of:
halting treatment when total inflow and total outflow of rinsing aid are not equal, indicating leakage of rinsing aid into the patient's body.
18. A bursitis treatment method according to claim 1 , further comprising the step of:
insufflating the bursa, thereby breaching inner adhesions.
19. A bursitis treatment method according to claim 1 , further comprising the step of:
imaging the bursa with radio-opaque contrast medium and inspecting the location of the access device, determining the size and extension of the bursa, and excluding extravasation and/or pre-existing connections to a joint space.
20. A bursitis treatment method according to claim 1 , further comprising the step of:
imaging the bursa with a thermal camera to obtain information on the temperature distribution in the bursa and along a membrane surface of the bursa, and using the obtained information to control at least one of said temperature, a flow rate of the rinsing aid, and a treatment time interval.
21. A bursitis treatment method according to claim 1 , further comprising the step of:
filling the bursa with the rinsing aid and holding the entire bursa wall evenly at said temperature.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/728,897 US9764071B2 (en) | 2010-01-26 | 2015-06-02 | Bursitis treatment device and method |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10000758A EP2347777A1 (en) | 2010-01-26 | 2010-01-26 | Bursitis treatment device and method |
EP10000758 | 2010-01-26 | ||
BE2010/0748 | 2010-12-21 | ||
PCT/EP2011/000317 WO2011091990A1 (en) | 2010-01-26 | 2011-01-26 | Bursitis treatment device and method |
US14/728,897 US9764071B2 (en) | 2010-01-26 | 2015-06-02 | Bursitis treatment device and method |
Related Parent Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/575,028 Division US9233194B2 (en) | 2010-01-26 | 2011-01-26 | Bursitis treatment device and method |
PCT/EP2011/000317 Division WO2011091990A1 (en) | 2010-01-26 | 2011-01-26 | Bursitis treatment device and method |
US13/996,962 Division US9091001B2 (en) | 2010-12-21 | 2011-12-21 | Shed-forming device for a weaving machine |
PCT/EP2011/006456 Division WO2012084213A2 (en) | 2010-12-21 | 2011-12-21 | Shed-forming device for a weaving machine |
Publications (3)
Publication Number | Publication Date |
---|---|
US20150297809A1 US20150297809A1 (en) | 2015-10-22 |
US20160287764A2 true US20160287764A2 (en) | 2016-10-06 |
US9764071B2 US9764071B2 (en) | 2017-09-19 |
Family
ID=42235925
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/575,028 Active US9233194B2 (en) | 2010-01-26 | 2011-01-26 | Bursitis treatment device and method |
US14/728,897 Active 2031-07-29 US9764071B2 (en) | 2010-01-26 | 2015-06-02 | Bursitis treatment device and method |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/575,028 Active US9233194B2 (en) | 2010-01-26 | 2011-01-26 | Bursitis treatment device and method |
Country Status (6)
Country | Link |
---|---|
US (2) | US9233194B2 (en) |
EP (2) | EP2347777A1 (en) |
JP (1) | JP5827241B2 (en) |
CN (1) | CN102802690A (en) |
BR (1) | BR112012018356A2 (en) |
WO (1) | WO2011091990A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013021833A1 (en) | 2011-08-10 | 2013-02-14 | 日本電気株式会社 | Wireless communication system, wireless communication method, base station, mobile terminal, method for controlling base station, method for controlling mobile terminal, and control program for base station or mobile terminal |
US9492071B2 (en) * | 2012-04-05 | 2016-11-15 | Stryker Corporation | In-joint sensor for a surgical fluid management pump system |
US20170106199A1 (en) | 2015-10-16 | 2017-04-20 | Brady L. WOOLFORD | Integrated pump control for dynamic control of plasma field |
US11602325B2 (en) * | 2018-03-01 | 2023-03-14 | Hsueh-Chih Yu | Ultrasonic guidance of subacromial bursa |
CN111035841B (en) * | 2020-02-25 | 2023-04-25 | 林高阳 | Medical multifunctional flushing drainage pipeline |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56128133A (en) * | 1980-03-14 | 1981-10-07 | Olympus Optical Co | Display apparatus of endoscope |
US4696303A (en) * | 1982-05-07 | 1987-09-29 | Michael Litman | Portable heat treatment system |
US5329936A (en) * | 1991-02-04 | 1994-07-19 | Citation Medical Corporation | Portable arthroscope with periscope optics |
US5322504A (en) * | 1992-05-07 | 1994-06-21 | United States Surgical Corporation | Method and apparatus for tissue excision and removal by fluid jet |
US5312327A (en) * | 1992-10-09 | 1994-05-17 | Symbiosis Corporation | Cautery override safety systems endoscopic electrosurgical suction-irrigation instrument |
JP3354652B2 (en) * | 1993-09-01 | 2002-12-09 | テルモ株式会社 | Chemical solution administration device |
US5382229A (en) * | 1993-09-21 | 1995-01-17 | Abbott Laboratories | Irrigation solution re-circulating system |
US5616120A (en) * | 1995-02-06 | 1997-04-01 | Andrew; Mark S. | Method and apparatus for lenticular liquefaction and aspiration |
DE19652381C1 (en) * | 1996-12-04 | 1998-07-16 | Richard Dipl Ing Korejwo | Operating system with gas or liquid pump for minimal-invasive surgery |
US6030359A (en) * | 1996-12-11 | 2000-02-29 | Northgate Technologies Inc | Apparatus and method for delivering fluid flow to a surgical site |
US6440103B1 (en) * | 1999-03-17 | 2002-08-27 | Surgijet, Inc. | Method and apparatus for thermal emulsification |
US6193683B1 (en) * | 1999-07-28 | 2001-02-27 | Allergan | Closed loop temperature controlled phacoemulsification system to prevent corneal burns |
JP2001231854A (en) * | 2000-02-21 | 2001-08-28 | Nikkiso Co Ltd | Medical liquid conduit |
US6869430B2 (en) * | 2000-03-31 | 2005-03-22 | Rita Medical Systems, Inc. | Tissue biopsy and treatment apparatus and method |
WO2002065930A1 (en) | 2001-02-09 | 2002-08-29 | Tushar Navneetlal Shah | Apparatus for endometrial ablation |
US20040152990A1 (en) * | 2003-01-29 | 2004-08-05 | Mackool Richard J. | Monitoring thermal conditions to vary operation of an ultrasonic needle tip of a surgical instrument |
US20050148934A1 (en) * | 2003-12-24 | 2005-07-07 | Mallinckrodt Inc. | Fluid infusion apparatus with an insulated patient line tubing for preventing heat loss |
EP1748722A4 (en) * | 2004-01-29 | 2009-11-11 | Cannuflow Inc | Atraumatic arthroscopic instrument sheath |
US8025638B2 (en) * | 2004-05-21 | 2011-09-27 | Keio University | Balloon catheter, medical apparatus and method for treating living organ |
WO2007070584A2 (en) * | 2005-12-16 | 2007-06-21 | Access Scientific | Needle constructed with a transparent or translucent material |
US8034018B2 (en) * | 2007-12-20 | 2011-10-11 | Bausch & Lomb Incorporated | Surgical system having means for stopping vacuum pump |
US8496652B2 (en) | 2008-06-06 | 2013-07-30 | Ethicon, Inc. | Balloon catheter systems and methods for treating uterine disorders |
-
2010
- 2010-01-26 EP EP10000758A patent/EP2347777A1/en not_active Withdrawn
-
2011
- 2011-01-26 EP EP11701941.4A patent/EP2528636B8/en active Active
- 2011-01-26 US US13/575,028 patent/US9233194B2/en active Active
- 2011-01-26 BR BR112012018356A patent/BR112012018356A2/en not_active Application Discontinuation
- 2011-01-26 WO PCT/EP2011/000317 patent/WO2011091990A1/en active Application Filing
- 2011-01-26 JP JP2012549295A patent/JP5827241B2/en active Active
- 2011-01-26 CN CN2011800135605A patent/CN102802690A/en active Pending
-
2015
- 2015-06-02 US US14/728,897 patent/US9764071B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2528636B1 (en) | 2016-05-11 |
US9764071B2 (en) | 2017-09-19 |
JP2013517813A (en) | 2013-05-20 |
EP2528636A1 (en) | 2012-12-05 |
EP2528636B8 (en) | 2016-11-02 |
BR112012018356A2 (en) | 2016-04-26 |
US20150297809A1 (en) | 2015-10-22 |
CN102802690A (en) | 2012-11-28 |
WO2011091990A1 (en) | 2011-08-04 |
EP2347777A1 (en) | 2011-07-27 |
JP5827241B2 (en) | 2015-12-02 |
US9233194B2 (en) | 2016-01-12 |
US20120310149A1 (en) | 2012-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9764071B2 (en) | Bursitis treatment device and method | |
US11849991B2 (en) | Integrity testing method and apparatus for delivering vapor to the uterus | |
US10575898B2 (en) | Systems and methods for performing endometrial ablation | |
CN102355856B (en) | System and method for monitoring bioimpedance and respiration | |
US9788881B2 (en) | Thermal ablation system with dispensable therapeutic | |
US20130267939A1 (en) | Methods and Apparatus for Ablating Lung Nodules with Vapor | |
US8814851B2 (en) | Thermal ablation system | |
US20220265201A1 (en) | Methods and Apparatus for Determining the Integrity of a Bodily Cavity | |
EP2200548A1 (en) | Fluid flowing device and method for tissue diagnosis or therapy | |
WO2004082491A1 (en) | Method and device for delivering a substance to tissue layers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VESALIUS MEDICAL TECHNOLOGIES BVBA, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN DEN BOSSCHE, JOHAN LIONEL;MULIER, STEFAAN MICHIEL MARIA;MULIER, KRISTOFFEL PIETER MARIA;AND OTHERS;SIGNING DATES FROM 20150504 TO 20150506;REEL/FRAME:036939/0049 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |